CAR T-cell immunotherapy of B-cell malignancy: the story so far.
CAR T-cell immunotherapy of B-cell malignancy: the story so far.
复制标题
DOI：
10.1177/2515135520927164
复制
发表时间：
2020-01-01
影响因子：
--
通讯作者：
Maher, John
中科院分区：
文献类型：
--
作者：
Halim, Leena;Maher, John
嵌合抗原受体(CAR)T细胞免疫治疗在治疗化疗耐药或难治性B细胞恶性肿瘤方面取得了前所未有的疗效。关键的抗CD19 CAR T细胞第二阶段试验取得了令人振奋的结果，导致美国食品和药物管理局和欧洲药品管理局批准了两种具有里程碑意义的CD19特异性CAR T细胞产品。然而，与CAR T细胞治疗相关的几个问题仍然没有解决，例如严重毒性的管理以及抗原阳性和抗原阴性复发的频繁发生。尽管如此，临床前研究正在以前所未有的速度发展，以开发创新的解决方案来解决这些问题。在此，我们总结了以CD19为靶点的CAR T细胞免疫治疗的最新临床进展和结果，并讨论了可能进一步提高该方法的成功率、安全性和广泛适用性的新策略。
Chimeric antigen receptor (CAR) T-cell immunotherapy has achieved unprecedented efficacy in the treatment of chemotherapy-resistant or refractory B-cell malignancies. Promising results from pivotal anti-CD19 CAR T-cell phase II trials have led to landmark approvals of two CD19-specific CAR T-cell products by the United States Food and Drug Administration and European Medicines Agency. However, several issues associated with CAR T-cell treatment remain unresolved, such as the management of severe toxicities and the frequent occurrence of both antigen-positive and antigen-negative relapse. Nonetheless, pre-clinical research is advancing at an unprecedented pace to develop innovative solutions to address these issues. Herein, we summarise recent clinical developments and outcomes of CD19-targeted CAR T-cell immunotherapy and discuss emerging strategies that may further improve the success, safety and broadened applicability of this approach.